A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer

This randomized phase II trial studies cisplatin and etoposide to see how well they work when
given with or without Hedgehog inhibitor GDC-0449 (vismodegib) or IGF-1R MOAB IMC-A12
(cixutumumab) in treating patients with extensive-stage small cell lung cancer. Drugs used in
chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Etoposide may slow the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Vismodegib may slow the growth of tumor cells. Monoclonal antibodies,
such as cixutumumab, may interfere with the ability of tumor cells to grow and spread. It is
not yet known whether giving cisplatin and etoposide are more effective when given together
with vismodegib or cixutumumab in treating small cell lung cancer.